Kuros Biosciences AG (CSBTF)
- Previous Close
9.05 - Open
8.69 - Bid --
- Ask --
- Day's Range
9.05 - 9.05 - 52 Week Range
1.89 - 9.05 - Volume
19 - Avg. Volume
1,285 - Market Cap (intraday)
333.753M - Beta (5Y Monthly) 0.91
- PE Ratio (TTM)
-- - EPS (TTM)
-0.42 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold use to fill bony voids for a predictable fusion; MagnetOs Easypack Putty, a ready-to-use mold to be implanted in any intervertebral disc space or posterolateral spine level; and Magnetos Flex Matrix, an open matrix bone graft. Its Fibrin-PTH pipeline products comprise KUR-111 and KUR-113 that are in Phase 2b clinical trials for trauma indications; KUR-113 that is in Phase 2a clinical trial for spinal indications. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.
www.kuros.chRecent News: CSBTF
Performance Overview: CSBTF
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CSBTF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CSBTF
Valuation Measures
Market Cap
277.83M
Enterprise Value
265.01M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.99
Price/Book (mrq)
5.37
Enterprise Value/Revenue
7.90
Enterprise Value/EBITDA
-25.46
Financial Highlights
Profitability and Income Statement
Profit Margin
-40.90%
Return on Assets (ttm)
-7.01%
Return on Equity (ttm)
-21.86%
Revenue (ttm)
33.56M
Net Income Avi to Common (ttm)
-13.73M
Diluted EPS (ttm)
-0.42
Balance Sheet and Cash Flow
Total Cash (mrq)
14.21M
Total Debt/Equity (mrq)
3.90%
Levered Free Cash Flow (ttm)
-7.29M
Company Insights: CSBTF
CSBTF does not have Company Insights